Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.

NCT Number	NCT05597345
Lead Sponsor	University of Rochester Collaborators: Karyopharm Therapeutics Inc
Conditions	Smoldering Multiple Myeloma
Enrollment	15 participants
Start Date	2023-08-21
Primary Completion	2024-10-29 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-10